HB1902 updates Virginia’s health data reporting and prescription monitoring laws to give the state more information about nonfatal opioid overdoses and to require prescribers to check that information in certain circumstances. The bill amends the Virginia Patient Level Data System provisions so that, when a patient has experienced a nonfatal opioid overdose, the Board of Health must transmit admission, transfer, and discharge data to the Department of Health Professions for use in the Prescription Monitoring Program (PMP). It also continues existing patient-level and outpatient claims reporting requirements for hospitals, physicians, oral and maxillofacial surgeons, and state agencies that cover outpatient services.
The bill also revises practitioner obligations under the PMP. Under the version effective until July 1, 2027, prescribers must be registered with the PMP and, when starting a new course of opioid treatment expected to last more than seven consecutive days, request PMP information to determine whether the patient is receiving other covered substances and whether the patient has experienced an opioid overdose. The bill keeps similar requirements for prescribers treating opioid use disorder and for practitioners issuing written certifications for cannabis oil. It also preserves several exceptions, including hospice, palliative care, inpatient hospital admission or discharge, nursing home or assisted living settings with a sole source pharmacy, and situations where the PMP is unavailable or inaccessible due to emergency or technical failure.
Beginning July 1, 2027, the bill changes the trigger for mandatory PMP checks to new courses of treatment involving benzodiazepines or opiates anticipated to last more than 90 consecutive days, rather than the shorter opioid-only threshold in the earlier version. It also authorizes the Secretary of Health and Human Resources to publish a list of low-abuse-potential benzodiazepines or opiates that are exempt from the PMP-check requirement, and it adds an exemption for pain management related to dialysis or cancer treatment. The cannabis-oil certification check remains in place.
The bill’s impact is to expand the use of overdose-related health data in prescribing oversight and to strengthen the PMP as a tool for identifying risky combinations of controlled substances. It affects the Board of Health, the Department of Health Professions, prescribers, hospitals, outpatient facilities, and state agencies that submit claims data, while also reinforcing confidentiality limits on how overdose information may be shared with practitioners.
The overall sentiment appears strongly favorable and largely noncontroversial. The bill advanced through subcommittees, full committees, and floor votes with overwhelming support in both chambers, including unanimous or near-unanimous committee votes and a 96-2 House vote and 40-0 Senate vote. The main policy tension is limited: the bill balances expanded overdose monitoring against provider burden by preserving exceptions for hospice, inpatient, emergency, and certain long-term or specialized treatment settings, and by allowing future exemptions for low-risk drugs and cancer or dialysis pain management.
HB1902 amends Code of Virginia §§ 32.1-276.6 and 54.1-2522.1 to require transmission of nonfatal opioid overdose admission/transfer/discharge data from the Board of Health to the Department of Health Professions for use in the Prescription Monitoring Program, and to revise when prescribers must query the PMP before initiating certain controlled-substance treatments. It affects reporting duties for hospitals, physicians, oral and maxillofacial surgeons, state agencies, and prescribers, while preserving confidentiality and creating specific exemptions and a delayed effective-date framework for the prescribing requirements.
The bill appears to have broad bipartisan support and little recorded opposition. It moved through committee and floor votes with large margins, including unanimous committee actions in several stages and only two no votes in the House and none in the Senate. The discussion record provided contains no transcript-based criticism, suggesting the measure was viewed primarily as a public-health and prescription-safety update rather than a controversial policy change.
The main points of contention are likely practical rather than ideological: how far to expand mandatory PMP checks, how much additional administrative burden to place on prescribers, and how to protect legitimate pain and specialty care from unnecessary barriers. The bill addresses these concerns by carving out exceptions for hospice, palliative care, inpatient settings, nursing homes and assisted living facilities with a sole source pharmacy, emergency or technical outages, and later by exempting certain low-abuse-potential drugs and dialysis/cancer pain management. No specific opposing stakeholder positions are recorded in the provided materials.